Compositions and methods to promote wound healing

Abstract

The present disclosure describes compositions and methods to promote wound healing. The compositions and methods include an interleukin-1 beta (IL-1β) receptor antagonist (IL-1Ra), such as anakinra. The IL-1Ra can be administered topically to a chronic wound including a diabetic ulcer.

What is claimed is: 
     
         1 . A topical composition comprising a therapeutic agent consisting of a therapeutic protein consisting of the sequence provided in SEQ ID NO: 26 (anakinra) in a therapeutically effective amount. 
     
     
         2 . The topical composition of  claim 1 , further comprising an interleukin-1 receptor antagonist (IL-1Ra). 
     
     
         3 . The topical composition of  claim 2 , wherein the IL-1Ra comprises the sequence shown in SEQ ID NO: 24. 
     
     
         4 . The topical composition of  claim 2 , wherein the composition is a gel, ointment, paste, lotion, powder, spray, or cream. 
     
     
         5 . The topical composition of  claim 2 , further comprising a thickening agent. 
     
     
         6 . The topical composition of  claim 5 , wherein the thickening agent is carboxymethylcellulose sodium. 
     
     
         7 . The topical composition of  claim 2 , further comprising a surfactant. 
     
     
         8 . The topical composition of  claim 7 , wherein the surfactant is a co-polymer having the formula 
       
         
           
           
               
               
           
         
       
       wherein x is 2 to 130, y is 15 to 70, and z is 2 to 130. 
     
     
         9 . The topical composition of  claim 1 , further comprising a buffer. 
     
     
         10 . The topical composition of  claim 9 , wherein the buffer comprises Phosphate Buffered Saline (PBS). 
     
     
         11 . The topical composition of  claim 1 , formulated as an additive to a wound dressing. 
     
     
         12 . The method of  claim 11 , wherein the wound dressing comprises an adhesive bandage. 
     
     
         13 . The topical composition of  claim 1 , further comprising a platelet-derived growth factor and/or Becaplermin. 
     
     
         14 . The topical composition of  claim 1 , which is formulated to promote healing of a chronic wound in a diabetic subject.